Keywords: Patents, "Patent cliff", R&D
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
Article | 24 November 2009
As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff,’ Big Pharma is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines. In an effort to mitigate the impact, Big Pharma is seemingly investing as much time and energy into diversification as R&D. However, a new report by independent market analyst Datamonitor suggests that diversifying away from the core business of developing prescription drugs is not the cure to the pending ails of the patent cliff.
< Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
